Two late-stage oncology signals highlighted breast cancer development and treatment strategy refinement. A phase 3 evERA trial in the New England Journal of Medicine reported that adding giredestrant to everolimus nearly doubled time without progression in patients with metastatic breast cancer. In a separate real-world analysis, researchers reported that tumor hormone receptor levels may help forecast which patients benefit most from standard advanced breast cancer therapy, using data from more than 4,100 patients. A broader commentary also argued that 2024–2025 care is shifting toward precision-guided de-escalation—reducing treatment intensity for selected patients—while reinforcing the need for evidence-based selection strategies.